I-Tositumomab in lymphoma

Area of Science:

• Oncology
• Nuclear Medicine
• Immunotherapy

Background:

• Radioimmunoconjugates, specifically radioisotope-bound monoclonal antibodies, offer targeted radiation delivery to lymphoma sites.
• Initial studies of iodine-131 tositumomab (131I-tositumomab) in non-Hodgkin lymphoma (NHL) indicate potential benefits for relapsed or refractory indolent disease.
• Widespread adoption is limited by concerns regarding toxicity and uncertain long-term efficacy.

Purpose of the Study:

• To systematically review and evaluate the evidence on the benefits and risks of 131I-tositumomab in lymphoma treatment.
• To identify predictors of response and toxicity associated with 131I-tositumomab therapy.
• To assess the role of pre-treatment dosimetry and imaging in guiding 131I-tositumomab use.

Main Methods:

• A comprehensive literature search was conducted to identify relevant trials.
• Eighteen trials investigating 131I-tositumomab in adult patients with NHL were included in the review.
• Data on response rates, time to progression, survival, toxicity, and predictive factors were analyzed.

Main Results:

• Overall response rates for 131I-tositumomab in relapsed/refractory indolent NHL ranged from 67% to 83%.
• In follicular NHL patients refractory to rituximab, response rates were 65%-72%.
• Clear improvements in time to progression or survival were not established in rituximab-naïve patients with relapsed/refractory indolent or transformed NHL.

Conclusions:

• 131I-tositumomab demonstrates activity in relapsed and refractory non-Hodgkin lymphoma.
• The agent should be considered for selected patients with relapsed or refractory NHL.
• Further investigation is warranted to optimize patient selection and manage potential toxicities for long-term benefit.